Previous 10 | Next 10 |
2023-07-13 09:30:00 ET The stock market rewards innovation, especially when it comes to new products and/or services that create or disrupt entire industries. Some of the best-performing stocks in the past two decades have been fueled by advances in cutting-edge areas such as artificial int...
2023-07-06 15:42:08 ET With the uptick of volatility in the stock market today, there’s no question as to why penny stocks are red hot. Whether the broader markets are risk-on or risk-off, the stock market is crashing or rallying, or if there’s a significant global catalys...
2023-07-06 11:54:56 ET Shares of clinical-stage biotech company Caribou Biosciences (NASDAQ: CRBU) were up more than 58% as of 11:15 a.m. ET on Thursday after Pfizer (NYSE: PFE) made a $25 million equity investment in the company. The healthcare stock is up more than 3% ...
-- Pfizer purchases $25 million of Caribou common shares -- -- Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou’s Scientific Advisory Board -- BERKELEY, Calif., July 06, 2023 (GLOBE NEWSWIRE...
2023-06-09 17:15:14 ET Gainers: PepGen ( PEPG ) +5% . Caribou Biosciences ( CRBU ) +4% . MaxCyte ( MXCT ) +4% . Noodles & Company ( NDLS ) +3% . Applied Digital ( APLD ) +3% . Losers: Couchbase ( BASE ...
2023-05-31 17:31:40 ET Summary We circle back to allogenic (off-the-shelf) cell therapy concern Caribou Biosciences for the first time since last Spring. Caribou is advancing three early-stage candidates within its pipeline, and the stock trades for the net cash on the company's b...
2023-05-09 17:28:13 ET Caribou Bioscience press release ( NASDAQ: CRBU ): Q1 GAAP EPS of -$0.46 beats by $0.03 . Revenue of $3.50M (+31.6% Y/Y) beats by $0.35M . For further details see: Caribou Bioscience GAAP EPS of -$0.46 beats by $0.03, revenue of $3....
-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at dose level 1 -- -- CB-012 IND application for r/r AML planned for H2 2023 ...
-- Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the ap...
2023-04-20 17:51:34 ET Gainers: ContextLogic ( WISH ) +28% . EyePoint Pharmaceuticals ( EYPT ) +7% . Caribou Biosciences ( CRBU ) +5% . Ocular Therapeutix ( OCUL ) +3% . Coherus BioSciences ( CHRS ) +3% . Losers: CRISPR T...
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
Caribou Biosciences Inc. Website:
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...
-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to...